{
    "nctId": "NCT04264468",
    "briefTitle": "Correlation Between Molecular Typing and Neoadjuvant Chemotherapy in Breast Cancer Patients Based on Mammaprint/Blueprint Test",
    "officialTitle": "Correlation Between Molecular Typing and Neoadjuvant Chemotherapy in Breast Cancer Patients Based on Mammaprint/Blueprint Test",
    "overallStatus": "UNKNOWN",
    "conditions": "Evaluation of the Value of Mammaprint Test Gene Variation in the Prediction of Neoadjuvant Chemotherapy for Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 150,
    "primaryOutcomeMeasure": "Recurrence Score variation after neoadjuvant chemotherapy",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Pathologically confirmed new breast cancer (invasive cancer)\n* Clinical stage II-III\n* women\n* Aged 25-80\n* At least 6 months of follow-up data, clinical diagnosis and treatment information and personal information available for follow-up are complete\n* Complete biological samples required for the study: fresh/frozen tissues/white tablets/wax blocks meeting the requirements of the experiment (before neoadjuvant chemotherapy)\n* Tumor markers and imaging data were complete\n* Neoadjuvant chemotherapy is commonly recommended by the standard NCCN guidelines\n\nExclusion Criteria:\n\n* Subjects refuse to participate\n* First diagnosis of stage I or IV breast cancer\n* Pathological diagnosis of concurrent (or previous) other malignant tumors\n* Prehistory breast cancer\n* Younger than 25 or older than 80\n* Clinical diagnosis and treatment information or biological samples required by the research institute do not meet the needs of the experiment",
    "sex": "FEMALE",
    "minimumAge": "25 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}